Blueprint Medicines Corp Stock
Blueprint Medicines Corp Stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
Cons
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| United Therapeutics | 0.640% | -1.663% | 11.405% | 55.677% | 6.529% | 119.585% | 218.322% |
| Iovance Biotherapeutics Inc. | -1.370% | -4.692% | 39.049% | 2.516% | 41.716% | -44.566% | -87.248% |
| Ligand Pharmaceuticals | -0.550% | 0.000% | 15.823% | 83.920% | 10.241% | 191.773% | 40.607% |
News
Offshore Titans: Transocean Buys Valaris for $5.8B
Transocean Ltd. (NYSE: RIG) has made the definitive move to cement its status as the undisputed leader in offshore drilling. By agreeing to acquire Valaris Limited (NYSE: VAL) in an all-stock
Why Ford's Deal With Amazon Is Bigger Than You Think
Ford Motor Company (NYSE: F) has made a groundbreaking move in automotive retail, announcing a partnership to sell its certified pre-owned (CPO) vehicles directly on Amazon (NASDAQ: AMZN).
This
Time to Take Notice: PEGA’s GenAI Blueprint Delivers Huge Q3 Beat
On a day that saw a handful of highly impressive earnings reports, tech stock Pegasystems (NASDAQ: PEGA) more than held its own. Shares blasted up by 15% on Oct. 22 as the market digested the

